the Board approved the re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092), Mr. Rajesh Shashikant Dalal (DIN: 03504969) and Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive ....
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare's Board re-appointed three Non-Executive Independent Directors — Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma — for a second term of five years (August 25, 2026 to August 24, 2031), subject to shareholder approval at the 8th AGM on August 19, 2026. The Board also approved Q4 and FY2026 audited results: Standalone revenue of Rs 789.32 million for Q4 and Rs 3,482.41 million for FY2026 with net profit of Rs 268.75 million; Consolidated revenue of Rs 19,099.27 million for Q4 and Rs 65,912.12 million for FY2026 with net profit of Rs 1,458.40 million. Auditors gave an unmodified opinion. Additionally, the Board approved fresh ESOP grants of 7,300 options and an acquisition of Vishal Surgicals & Vishal Surgicals & Medicals (partnership firm) through subsidiary Sai Pharma Distributors Pvt Ltd via slump sale. The company also struck off three non-operating subsidiaries during the year.
Re-appointment of all three independent directors signals board stability and continuity of governance. Strong consolidated profit growth (FY2026 PAT up ~36% YoY) and aggressive acquisition-driven expansion are positives for investors, though increased debt and working capital pressure warrant monitoring.